CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 128 filers reported holding CRINETICS PHARMACEUTICALS IN in Q1 2023. The put-call ratio across all filers is 0.00 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,880,817 | +136.2% | 197,741 | +43.1% | 0.04% | +150.0% |
| Q2 2023 | $2,490,112 | +20.5% | 138,186 | +7.4% | 0.01% | 0.0% |
| Q1 2023 | $2,067,050 | +6.1% | 128,708 | +20.9% | 0.01% | -12.5% |
| Q4 2022 | $1,948,913 | +31.5% | 106,498 | +41.1% | 0.02% | 0.0% |
| Q3 2022 | $1,482,000 | +77.5% | 75,453 | +68.5% | 0.02% | +100.0% |
| Q2 2022 | $835,000 | -51.3% | 44,769 | -42.7% | 0.01% | -20.0% |
| Q1 2022 | $1,715,000 | +15.8% | 78,135 | +49.9% | 0.01% | +25.0% |
| Q4 2021 | $1,481,000 | +155.8% | 52,112 | +89.4% | 0.01% | +100.0% |
| Q3 2021 | $579,000 | – | 27,513 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 3,375,169 | $84,379,000 | 7.91% |
| RA Capital Management | 1,875,209 | $46,880,000 | 2.52% |
| Perceptive Advisors | 2,587,953 | $64,698,000 | 1.48% |
| New Leaf Venture Partners, L.L.C. | 167,700 | $4,193,000 | 1.12% |
| Orbimed Advisors | 2,039,282 | $50,982,000 | 0.79% |
| Eventide Asset Management | 803,839 | $20,096,000 | 0.61% |
| Novo Holdings A/S | 135,009 | $3,375,000 | 0.47% |
| Opaleye Management Inc. | 36,000 | $900,000 | 0.27% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 490,000 | $12,250,000 | 0.03% |
| Baker Brothers Advisors | 132,985 | $3,325,000 | 0.02% |